FBLN2 antibodies are immunological reagents designed to detect and quantify the Fibulin-2 protein in research and diagnostic contexts. These antibodies are used to investigate FBLN2's roles in ECM organization, cell adhesion, and cancer biology .
Expression Dynamics: FBLN2 is highly expressed in terminal end buds (TEBs) during murine mammary gland puberty, localizing to cap cells and stromal regions .
Hormonal Regulation: Estrogen (E2) and progesterone (P) upregulate Fbln2 mRNA by 3.6–4.0 fold in pubertal mice .
Matrix Interactions: FBLN2 enhances epithelial cell adhesion to laminin, vitronectin, and fibronectin but does not directly affect migration .
Breast Cancer Prognosis: High Fbln2 mRNA levels correlate with improved distant metastasis-free survival in lymph node-negative (HR = 0.71, P = 0.03) and intermediate-grade (HR = 0.76, P = 0.05) breast cancers .
Tumor Suppression: FBLN2 knockdown in mammary epithelial cells disrupts BM integrity and reduces integrin β1 expression, promoting tumor invasiveness .
| Structure | % Age Score | Intensity Score | Quickscore |
|---|---|---|---|
| TEB | 6 | 3 | 18 |
| Duct | 4 | 1 | 4 |
| Patient Subgroup | Hazard Ratio (HR) | P-value |
|---|---|---|
| LN-negative | 0.71 | 0.03 |
| Grade II | 0.76 | 0.05 |
| Grade III | 1.32 | 0.023 |
Validation: Orthogonal RNAseq and immunofluorescence are used to confirm specificity .
Storage: Most antibodies are stable at −20°C in glycerol-based buffers .
Limitations: Cross-reactivity with other fibulin family members requires careful validation .